Robert D Little

ORCID

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 7

Top Venues

BMJ open

Journal of clinical medicine

Inflammatory bowel diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Robert D Little, Jo McKenzie, Ashish Srinivasan, Patrick Hilley, Robert B Gilmore, Desmond Chee, Manjeet Sandhu, Daniel Saitta, Elizabeth Chow, Lena Thin, Gareth J Walker, Gregory T Moore, Kate Lynch, Jane Andrews, Yoon K An, Robert V Bryant, Susan J Connor, Mayur Garg, Emily K Wright, Georgina L Hold, Jonathan P Segal, Alex Boussioutas, Peter De Cruz, Mark G Ward, Miles P Sparrow
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial. BMJ open 14 (7) (2024)
Robert D Little, Jo McKenzie, Ashish Srinivasan, Patrick Hilley, Robert B Gilmore, Desmond Chee, Manjeet Sandhu, Daniel Saitta, Elizabeth Chow, Lena Thin, Gareth J Walker, Gregory T Moore, Kate Lynch, Jane Andrews, Yoon K An, Robert V Bryant, Susan J Connor, Mayur Garg, Emily K Wright, Georgina L Hold, Jonathan P Segal, Alex Boussioutas, Peter De Cruz, Mark G Ward, Miles P Sparrow
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial. BMJ open 14 (7) (2024)
Robert D Little, Jo McKenzie, Ashish Srinivasan, Patrick Hilley, Robert B Gilmore, Desmond Chee, Manjeet Sandhu, Daniel Saitta, Elizabeth Chow, Lena Thin, Gareth J Walker, Gregory T Moore, Kate Lynch, Jane Andrews, Yoon K An, Robert V Bryant, Susan J Connor, Mayur Garg, Emily K Wright, Georgina L Hold, Jonathan P Segal, Alex Boussioutas, Peter De Cruz, Mark G Ward, Miles P Sparrow
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial. BMJ open 14 (7) (2024)
Robert D Little, Jo McKenzie, Ashish Srinivasan, Patrick Hilley, Robert B Gilmore, Desmond Chee, Manjeet Sandhu, Daniel Saitta, Elizabeth Chow, Lena Thin, Gareth J Walker, Gregory T Moore, Kate Lynch, Jane Andrews, Yoon K An, Robert V Bryant, Susan J Connor, Mayur Garg, Emily K Wright, Georgina L Hold, Jonathan P Segal, Alex Boussioutas, Peter De Cruz, Mark G Ward, Miles P Sparrow
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial. BMJ open 14 (7) (2024)
Robert D Little, Adrian Swaine, Rebecca Reynolds, David J Gibson, Mathilde Barrau, Francesca D'Errico, Rumneek Hampal, Miles P Sparrow, Xavier Roblin, Peter M Irving, Mark G Ward
Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn's Disease: A Retrospective, International Multicenter Study. Inflammatory bowel diseases (2023)
Kathryn Demase, Cassandra K Monitto, Robert D Little, Miles P Sparrow
The Role of Low-Dose Oral Methotrexate in Increasing Anti-TNF Drug Levels and Reducing Immunogenicity in IBD. Journal of clinical medicine 12 (13) (2023)
Robert D Little, Mark G Ward, Emily Wright, Asha J Jois, Alex Boussioutas, Georgina L Hold, Peter R Gibson, Miles P Sparrow
Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease-Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics. Journal of clinical medicine 11 (20) (2022)

Robert D Little.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Robert D Little